Phaseline

Companies › MiNK Therapeutics

MiNK Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Oncology, Respiratory; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
agenT-797
Innate lymphoid cell (ILC) therapy
–Phase 2Pneumonia; Metastatic Esophageal Carcinoma; Colorectal Cancer MetastaticJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07615010agenT-797Phase 2PneumoniaRespiratoryJun 2027
NCT06251973agenT-797Phase 2Metastatic Esophageal CarcinomaOncologyAug 2027
NCT07550088agenT-797Phase 2Colorectal Cancer MetastaticOncologySep 2028

From the company's SEC filings

Cash of $9m on 2026-06-30; operating cash outflow about $8m a year; runway about 14 months at that burn, to Aug 2027; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SPARK Biopharma NuvOx Allarity Therapeutics Rein Therapeutics CNS Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.